Evaluation of the Efficiency of Treatment with Rituximab for Systemic Scleroderma (A Case Report)
https://doi.org/10.20514/2226-6704-2021-11-1-72-75
Abstract
The article describes a clinical case of a progressive form of systemic scleroderma in a 39-year-old man. The patient has an acute course and rapid progression of the disease with a significant initial decrease in the forced vital capacity of the lungs, with signs of an unfavorable prognosis, such as a diffuse form, a high skin count (> 14), male sex, and high positivity for antibodies to Scl-70. In connection with the ineffectiveness of standard therapy with glucocorticoids and immunosuppressants at an early stage of the disease, the option of treatment with genetically engineered drugs (rituximab) was considered. As a result of the therapy, a positive trend was noted.
About the Authors
E. N. Harlamova
State Budgetary Educational ln-stitution of High Professional Education «Voronezh State Medical University n.a. N.N. Burdenko» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Evgenija N. Harlamova
Department of Hospital Therapy and Endocrinology
Voronezh
Ju. Ju. Karpenko
State Budgetary Educational ln-stitution of High Professional Education «Voronezh State Medical University n.a. N.N. Burdenko» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Department of Hospital Therapy and Endocrinology
Voronezh
References
1. Ananyeva L.P. Diagnosis and treatment of interstitial lung disease in scleroderma systematica. Modern Rheumatology Journal. 2018; 12(2): 12-21. doi.org/10.14412/1996-7012-2018-2-12-21. [In Russian].
2. Jordan S., Distler J.H, Maurer B., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74(6): 1188-94. doi: 10.1136/annrheumdis-2013-204522.
3. Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018; 195: 76-82. doi.org/10.1016/j.imlet.2018.01.002.
4. Ananyeva L.P., Koneva O.A., Desinova O.V., et al. Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation. Nauchno-Prakticheskaya Revmatologiya. 2019; 57(3): 265-273. doi: 10.14412/1995-4484-2019-265-273. [In Russian].
5. Khanna D., Distler J.H.W., Sandner P. et al. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord. 2016; 1(2): 186-193. doi: 10.5301/jsrd.5000207.
6. Fernandez-Codina A., Walker K.M., Pope J.E. Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheum. 2018; 70(11): 1820-1828. doi: 10.1002/art.40560.
7. E.L. Nasonov. Russian clinical guidelines. Rheumatology. 2017. [Electronic resource]. URL: https://www.rosmedlib.ru/book/ISBN9785970442616.html. (date of the application: 10.10.2020). [In Russian].
Review
For citations:
Harlamova E.N., Karpenko J.J. Evaluation of the Efficiency of Treatment with Rituximab for Systemic Scleroderma (A Case Report). The Russian Archives of Internal Medicine. 2021;11(1):72-75. https://doi.org/10.20514/2226-6704-2021-11-1-72-75
Views:
1467
Email this article 